The Roles of protein kinase d2 in chemoresistant breast cancer cell lines

Download
2014
Alpsoy, Aktan
Even though chemotherapy keeps its position as the most preferred and potent strategy of cancer treatment, resistance of tumor to the anti-neoplastic drug poses an obstacle for chemotherapy success. Multidrug resistance (MDR) is a phenomenon that is defined as the intrinsic or acquired resistance against structurally and functionally unrelated drugs. Acquisition of multidrug resistance can be through several distinct mechanisms such as increased drug efflux by ABC transporters, increased drug detoxification through phase I and II enzymes, altered death pathways and increased damage repair, making MDR a multifaceted problem that remodel many regulatory or metabolic circuits. MDR phenotype has also been linked to increased aggressiveness marked by mobility and invasiveness or vice versa. Protein kinase D2 (PKD2) is one of the isoforms in three-membered serine/threonine kinase family, PKD. PKD family members can possess redundant as well as specific roles on proliferation, survival, angiogenesis and motility, the events that are relevant to cancer. In glioblastoma, leukemia, colorectal, pancreas and breast cancer, tumor promoting and suppressing roles of PKD members have been shown. In particular, breast cancer, the most common cancer type in women, PKD2 and PKD3 appear to have oncogenic roles while PKD1 possesses tumor-suppressive functions. Specifically, PKD2 seems to be ubiquitous in many breast cancer types, while PKD1 and PKD3 are not. To this end, we aimed to characterize the ubiquitous member, PKD2, in a panel of breast cancer cell lines. We found that the expression of PKD2 does not differ between cell lines, whereas its basal level activity is higher in chemoresistant MCF7 derivatives compared to parental MCF7 cell line, implying that PKD2 may have role in drug resistance and associated phenotypes. Cell proliferation assay showed that PKD2 downregulation does not affect the drug resistance in MCF7/DOX cells. PKD2 knockdown also does not significantly change the expression of potential PKD targets that are implicated in MDR and apoptosis. MCF7/DOX cells are phenotypically different from parental cell line such that they have higher expression of epithelial to mesenchymal transition markers, higher mobility and invasive characteristics. Since PKD2 is also implicated in motility we checked whether PKD2 downregulation influences the migration of MCF7/DOX cells towards a chemoattractant. The migration assay showed that PKD2 downregulation suppresses the migration of MCF7/DOX cells. The data implied that under this experimental setup PKD2 did not alter the drug resistance whereas it changes the migration potential of doxorubicin resistant MCF7 cell line. Further research is needed to uncover the roles of other isoforms PKD1 and PKD3 as well as upstream regulators of PKD members in chemoresistance.

Suggestions

Synthesis of poly (dl-lactic-co-glycolic acid) coated magnetic nanoparticles for anti-cancer drug delivery
Tansık, Gülistan; Gündüz, Ufuk; Department of Biology (2012)
One of the main problems of current cancer chemotherapy is the lack of selectivity of anti-cancer drugs to tumor cells which leads to systemic toxicity and adverse side effects. In order to overcome these limitations, researches on controlled drug delivery systems have gained much attention. Nanoscale based drug delivery systems provide tumor targeting. Among many types of nanocarriers, superparamagnetic nanoparticles with their biocompatible polymer coatings can be targeted to an intented site by an extern...
Role of ABCB1 and ABCC1 Gene Induction on Survival in Locally Advanced Breast Cancer
Atalay, C.; DEMİRKAZIK, AHMET; Gündüz, Ufuk (2008-12-01)
Drug resistance to chemotherapy in patients with locally advanced breast cancer results in a decrease in treatment efficacy and in patient survival. This study aimed to evaluate the impact of ABCB1 and ABCC1 gene induction during chemotherapy on disease-free and overall survival of breast cancer patients.
Development and investigation of etoposide resistance in MCF-7 Breast cancer cell line
Kaplan, Esra; Gündüz, Ufuk; Department of Biology (2010)
Failure of chemotherapy in cancer patients because of development of drug resistance is a major problem. Alterations of DNA repair mechanisms and drug targets are among the important resistance mechanisms which are developed against topoisomerase II inhibitors etoposide and doxorubicin. Modifications in the expression levels of mismatch repair (MMR) genes due to resistance to topoisomerase II inhibitors are involved in breast cancer. In this study, etoposide resistant sublines were developed from MCF7 breas...
Reversal of breast cancer resistance protein mediated multidrug resistance in MCF7 breast adenocarcinoma cell line
Urfalı, Çağrı; Gündüz, Ufuk; Department of Biology (2011)
Resistance to various chemotherapeutic agents is a major problem in success of cancer chemotherapy. One of the primary reasons of development of multidrug resistance (MDR) is the overexpression of ATP binding cassette (ABC) transporter proteins. Breast cancer resistance protein (BCRP) belongs to ABC transporter family and encoded by ABCG2 gene. BCRP is mainly expressed in MDR1 (P-glycoprotein) lacking breast cancer cells. Overexpression of BCRP leads to efflux of chemotherapeutic agents at higher rates, the...
The role of 15-LOX-1 in resistance to chemotherapeutics
Kazan, Hasan Hüseyin; Gündüz, Ufuk; Department of Biology (2020)
Chemotherapy is one of the best options to treat cancer. However, drug resistance can limit the efficacy of chemotherapeutics. There have been several reasons for the cancer drug resistance including the export of the drug from cells, inactivation of drugs by enzymatic processes, mutations that limit the binding of the drugs to the target proteins, resistance to cell death mechanism by cellular manipulations and reorganization of the cell membrane. 15-Lipoxygenase-1 (15-LOX-1) is a member of the lipoxygenas...
Citation Formats
A. Alpsoy, “The Roles of protein kinase d2 in chemoresistant breast cancer cell lines,” M.S. - Master of Science, Middle East Technical University, 2014.